56TH ERA-EDTA CONGRESS OFFICIAL WEBSITE

ERA-EDTA BUD2019 banner 900x344 0418-1.jpg
ERA-EDTA BUD2019 banner 900x344 0418-2.jpg
ERA-EDTA BUD2019 banner 900x344 0418-3.jpg
panorama.jpg
Budapest-Citadella-s.jpg
Panorama-with-the-Chain-Bridge-s.jpg
panorama_3.jpg
panorama-4.jpg

    You are here

    • You are here:
    • Home > Scientific Programme

Scientific Programme

 

WELCOME LECTURE

 

Diseases of emergence
Rafael Yuste, New York, NY, USA

 
 

PLENARY LECTURES

 
Interface of molecular mechanisms, pathology and genetics of developmental kidney diseases
Sanjay Jain, Saint Louis, MO, USA
 
Single-cell transcriptomics in kidney disease
Katlin Susztak, Philadelphia, PA, USA
 
The pre-dialysis to renal replacement therapy transition
Csaba P. Kovesdy, Memphis, TN, USA
 
 

SPECIAL SYMPOSIA

 
Late Breaking Clinical Trials
 
ERA-EDTA Registry
 
ASN Highlights
 
Nephrology pearls (Special closing session)
 
 

SYMPOSIA

 

FLUID & ELECTROLYTES, TUBULAR TRANSPORT, RENAL PHYSIOLOGY

 

Phosphate and FGF23
1. FGF23 signalling in the kidney
Reinhold Erben, Vienna, Austria
2. Regulation of FGF23
Mariano Rodriguez, Cordoba, Spain
3. Phosphate toxicity in the kidney

 

HEREDITARY DISORDERS, DEVELOPMENT, PREGNANCY, PAEDIATRIC NEPHROLOGY

 

Redefining the ontology of kidney diseases using genomic analysis
1. Genetic landscape of hereditary amyloidosis
2. What’s up in hereditary tubulo-interstitial nephritis?
Stanislas Kmoch, Prague, Czech Republic
3. Adult-onset ESRD of unknown aetiology: when should we think genetics?
Nine Knoers, Groningen, The Netherlands

 

Novel therapies in hereditary kidney diseases
1. New therapeutic targets in Alport syndrome
Roser Torra, Barcelona, Spain
2. Targeted therapies in ADPKD: what will be in the pipeline in 2020?
Ron T. Gansevoort, Groningen, Netherlands
3. Therapeutic management of cystinuria: today and tomorrow

 

Paediatric Nephrology
1. Childhood nephrotic syndrome: lessons from the PODONET registry
Beata S. Lipska-Ziętkiewicz, Gdańsk, Poland
2. Evidence based treatment of minimal change nephrotic syndrome: lessons from the PREDNOS trials
Nicholas Webb, Manchester, United Kingdom
3. Novel therapies for childhood minimal change nephrotic syndrome
Marina Vivarelli, Rome, Italy
4. Blood pressure in children
Kjell Tullus, London, United Kingdom

 

Pregnancy
1. AKI during pregnancy: no longer an issue?
2. Lupus nephritis and pregnancy: concerns and management
3. Preventing preeclampsiaa

 

GLOMERULAR DISEASES & GENERAL CLINICAL NEPHROLOGY

 

The many faces of monoclonal gammopathy of undetermined significance
1. MGRS classification: bringing order to the nomenclature chaos
2. MGRS diagnosis: establishing causality is the hardest job
Jolanta Malyszko, Warsaw, Poland
3. MGRS treatment: should we follow the haematologist or take the lead?

 

Molecular mechanisms of kidney atrophy and fibrosis
1. The cannabinoid system and CKD progression
Joseph Tam, Jerusalem, Israel
2. Does less fibrosis improve renal function? Insights from collagen I-deficiency
3. Pathology and mechanisms of interstitial granuloma formation
Peter Boor, Aachen, Germany

 

ANCA-associated vasculitis
1. Extrarenal involvement in AAV and its impact on the outcome of patients
Vladimir Tesar, Prague, Czech Republic
2. ANCA-associated vasculitis in the elderly and very elderly
3. Should the anti-PR3 and anti-MPO patients be treated in a different way?

 

Lupus nephritis
1. Histologic classification of lupus nephritis – time for a change?
Ingeborg M. Bajema, Leiden, Netherlands
2. Pathogenesis of SLE and systemic lupus nephritis – what is new?
Hans-Joachim Anders, Munich, Germany
3. Biologic therapy in lupus nephritis – where are we now?

 

Primary glomerulonephritides
1. Anti-THSD7A-positive disease, outcome and treatment
Rolf A.K. Stahl, Hamburg, Germany
2. Spontaneous remission in membranous nephropathy – how long should we wait?
Fernando Fervenza, Rochester, MN, USA
3. Serology-based algorithm of the treatment of membranous nephropathy
4. What is the optimal approach to the treatment of IgA nephropathy in 2019?
Jürgen Floege, Aachen, Germany

 

CKD - PATHOPHYSIOLOGY, EPIDEMIOLOGY, PREVENTION, PROGRESSION, AGEING

 

The many facets of hypoxia in CKD
1. Hypoxia and CKD progression
2. Sleep disordered breathing: a pervasive problem in CKD
3. Intradialysis hypoxia
Peter Kotanko, New York, NY, United States
4. Lessons from Mesoamerican nephropathy
Marc de Broe, Antwerp, Belgium

 

Neuroinflammation and CKD
1. The gut-brain axis, b2microglobulin and neuroinflammation: a re-interpretation of an old story?
Michel Jadoul, Brussels, Belgium
2. Anti-inflammatory role of the parasympathetic system in CKD
3. Neuroinflammation and hypertension

 

The role of diet in the prevention of CKD progression: food for thought
1. Kidney disease and the westernization and industrialization of food
2. Dietary protein restriction: PRO
Denis Fouque, Lyon, France
3. Dietary protein restriction: AGAINST
Marc Vervloet, Amsterdam, Netherlands
4. Sodium as a regulator of immunity

 

The gut-kidney-cardiovascular axis
1. Gut microbiota and microbial metabolism in CKD across stages of diseases
Griet Glorieux, Ghent, Belgium
2. Gut dysbiosis and thrombosis
3. Gut dysbiosis and vascular calcification
Ziad Massy, Paris, France

 

The paradox of estimated GFR in the era of precision medicine
1. Overview of the error of creatinine and cystatin-c-based formulas in clinical practice
Esteban Porrini, La Laguna, Spain
2. Measured GFR in clinical practice, the Swedish experience
Anders Christensson, Malmö, Sweden
3. Which method to measure GFR and in which clinical conditions?
Pierre Delanaye, Liège, Belgium
4. MRI approaches to asses kidney injury and function

 

New insights in molecular mechanism of cardiovascular diseases in CKD
1. Oxidative stress on myocardial function in CKD
Leticia Prates Roma, Homburg/Saar, Germany
2. Post-translational lipoprotein modification in uraemia
Thimoteus Speer, Homburg/Saar, Germany
3. Atherosclerosis, cardiac remodelling and CKD

 

END-STAGE RENAL DISEASE, HAEMODIALYSIS

 

Haemodialysis. From incremental approaches to frequent treatments
1. The concept of incremental dialysis
Carlo Basile, Acquaviva delle Fonti, Italy
2. Clinical experiences with incremental haemodialysis schedules
Kamyar Kalantar-Zadeh, Orange, CA, United States
3. Quality of life and haemodialysis frequenc

 

Controversy: does haemodiafiltration improve patient outcomes and survival?
1. No
Francesco Locatelli, Lecco, Italy
2. Yes
Peter J. Blankestijn, Utrecht, Netherlands
3. Increasing convection: what happens to the different uraemic toxins when increasing convection in post-dilutional HDF?
Angel Argiles Ciscart, Montpellier, France

 

Start dialysis? Stop dialysis? - Challenging conversations
1. Dialysis or conservative care?
Wim Van Biesen, Ghent, Belgium
2. Is this the time to consider dialysis withdrawal?
Monika Lichodziejewska-Niemierko, Gdańsk, Poland
3. Different conversations for different ethnic groups?
Edwina Brown, London, United Kingdom
4. Clinical Practice Guideline on management of older patients with advanced chronic kidney disease
Adrian Covic, Iași, Romania

 

Delivering good quality dialysis - what should we measure?
1. Small solute clearance: what are the pitfalls?
2. Patient-reported outcomes: are these fit for purpose?
Ken Farrington, Stevenage, United Kingdom
3. Towards a multidimensional measure of dialysis adequacy?

 

The hidden risks of haemodialysis
1. Silent ischemia during haemodialysis
2. Haemodynamic instability and ischemic brain injury
Adrian Covic, Iași, Romania
3. Tolerability of extracorporeal treatments in 2019
4. Clinical Practice Guideline on Vascular Access
Maria Haller, Linz, Austria

 

CKD-MBD patterns and therapeutic approaches: update 2019
1. Klotho, a new player coming to age
Marc Vervloet, Amsterdam, Netherlands
2. New insights in pathogenesis and treatment of vascular calcification
Catherine Shanahan, London, United Kingdom
3. Osteoporosis in CKD, a diagnostic and therapeutic challenge on the move

 

HOME THERAPIES, PERITONEAL DIALYSIS

 

Optimizing peritoneal dialysis prescription
1. Why testing peritoneal membrane characteristics?
Johann Morelle, Brussels, Belgium
2. Optimizing PD initiation and reducing early switches to HD: Insights from PDOPPS
Simon Davies, Stoke-on-Trent, United Kingdom
3. Individualising prescription for residual renal function

 

Home haemodialysis: on the move
1. Reducing the costs of end stage renal disease while delivering quality health care: are home therapies the answer?
Wim Van Biesen, Ghent, Belgium
2. Striving to achieve an integrated home dialysis system
3. Vascular access in HHD: the Achilles tendon?
Sandip Mitra, Manchester, United Kingdom

 

Frail elderly: management best at home
1. Integrating geriatric assessment into routine dialysis care
Edwina Brown, London, United Kingdom
2. Outcomes on assisted PD
3. Integrating with community geriatric services
4. Addressing potentially inappropriate medications in older adults with kidney disease

 

TRANSPLANTATION & IMMUNOLOGY

 

Overcoming age with frailty evaluation in the kidney transplant recipient
1. Is frailty evaluation a precise evaluation of the patient with chronic disease?
Juan Jesus Carrero, Stockholm, Sweden
2. The best frailty evaluation before kidney transplantation
3. Outcomes of frail patients after kidney transplantation
Maria José Pérez-Sáez, Barcelona, Spain

 

Precision medicine for the sensitized transplant recipient. The TTT
1. Tailoring a transplant route for the sensitized patient on dialysis
2. Treating the patient while listed
3. Taking care: balancing immunosuppression avoiding weapons of mass destruction
Julio Pascual, Barcelona, Spain

 

Basic immunology and pathology
1. Necroinflammation in kidney transplantation
2. Polyoma nephropathy
Jan Ulrich Becker, Cologne, Germany
3. Banff update
Carmen Lefaucheur, Paris, France

 

Improving the organ donor pool
1. Controlled Cardiac Donor Death program in Spain: one vision for the future
Beatriz Dominguez Gil, Madrid, Spain
2. Kidney protection in living donors
Charles Ferro, Birmingham, United Kingdom
3. Compatibility barriers/Increasing the pool of marginal donors

 

HYPERTENSION, DIABETES, VASCULAR DISEASES

 

Improving outcomes in DKD
1. Renal inflammation: its pathogenetic role in diabetic kidney disease
Sydney Tang
, Hong Kong, Hong Kong
2. Basic science: SGLT2 inhibitors in the prevention of renal fibrosis
3. Update on SGLT2i in CKD
Christoph Wanner, Würzburg, Germany
4. GLP-1 receptor agonists in DKD: mechanisms and outcomes
Johannes F.E. Mann, Munich, Germany

 

Salt and disease: a changing scenario / Sodium: where is it? How does it harm? How could we intervene?
1. Salt and hypertension: a bacterial affair
2. Tissue sodium storage in end stage kidney disease
3. Gender and renal salt handling
4. Renal potassium sensing and control of sodium balance

 

Cardiovascular disease in CKD: risk factors and remedies
1. Why is the risk of stroke so high in CKD and in dialysis patients?
Sydney Tang, Hong Kong, Hong Kong
2. Clinical trials and research priorities in dialysis patients
3. Modifiable risk factors for cardiovascular disease in CKD: a hierarchical approach
Rajiv Agarwal, Indianapolis, IN, USA
4. China Kidney Network (CK-NET): Opportunities for Kidney Disease in the Era of Big Data

 

Digging the aetiology of hypertension
1. Biological insights from GWAS
2. Thrombotic microangiopathy and malignant hypertension
3. Insights from adverse effects of drugs
Petra Tesarova, Prague, Czech Republic
4. Out-of-office BP monitoring and BP variability in chronic kidney disease: current concepts and future directions

 

Blood pressure targets
1. Optimal BP target for renoprotection in CKD patients is <140/90
Mustafa Arici, Ankara, Turkey
2. Optimal BP target for renoprotection in CKD patients is <130/80
Pantelis Sarafidis, Thessaloniki, Greece
3. Managing resistant hypertension
Andrzej J. Wiecek, Katowice, Poland

 

ACUTE KIDNEY INJURY & INTENSIVE CARE NEPHROLOGY

 

AKI: current problems in clinical practice
1. To fill or not to fill: what is the evidence
2. Heart failure and AKI
3. Genetic variability and AKI
Michael Heung, Ann Arbor, United States
4. References to urinary tract disease in the Works of Thomas of Wroclaw (1297-1378), the Continuator of Arnaldo de Villanova's Medical Thought
Janusz Ostrowski, Warsaw, Poland

 

Renal Replacement Therapy in the Intensive Care Unit
1. Modality and dose: where do we stand?
2. When to start dialysis: the final answer?
Julien Maizel, Amiens, France
3. The intertwined relation between CKD and AKI: pitfalls and cobblestones

 
 

MINI LECTURES

 

Renal and intestinal oxalate transport, inflammation and CKD
Felix Knauf, Berlin, Germany

 

Autophagy in kidney diseases
Yoshitaka Isaka, Suita, Japan

 

Interallelic interactions of podocin

 

Personalised diagnosis and CKD prediction in genetic tubular disorders
Francesca Becherucci, Florence, Italy

 

Whole-exome sequencing in adults with CKD

 

New therapies in the Henoch-Schönlein syndrome
Roberta Fenoglio, Turin, Italy

 

Role of complement in the pathogenesis of IgA nephropathy
Rosanna Coppo, Turin, Italy

 
IgA Nephropathy: Evidences from China
 

PCSK9 in kidney disease
Danilo Fliser, Homburg/Saar, Germany

 

From human embryonic nephron stem cells to mature kidney tissue and regeneration
Benjamin Dekel, Ramat Gan, Israel

 

Regenerative medicine
Takashi Yokoo, Tokyo, Japan

 

Calciphylaxis
Vincent Brandenburg, Aachen, Germany

 

The Swedish Health databases and kidney research
Juan Jesus Carrero, Stockholm, Sweden

 

When should a nephrologist take over – stage 3b or 4 – current perspective
Goce Spasovski, Skopje, F.Y.R. of Macedonia

 

May we answer the question: “Doctor: how long may I live in dialysis”?
Jürgen Floege, Aachen, Germany

 

Is there room to improve dialysis stability? Should we change time, dialysis modality, dialysate solute concentrations, dialysate temperature, all of them or nothing of it?

 

How to measure residual renal function
Andrew Davenport, London, United Kingdom

 

New approaches to enhance removal, particularly of protein bound solutes
Joachim Jankowski, Aachen, Germany

 

The global fluid study

 

Self-care improves patient outcomes: what is the evidence?
Martin Wilkie, Sheffield, United Kingdom

 

Molecular targets in renal transplantation: reality or fiction?
Michael Mengel, Edmonton, Canada

 

The largest trial ever done in transplantation: TRANSFORM, with results at 3 years
Julio Pascual, Barcelona, Spain

 

Vitamin D after kidney transplantation
Markus Ketteler, Coburg, Germany

 

Vascular calcification and Iron metabolism – are they connected?
József Balla, Debrecen, Hungary

 

Bariatric surgery: untangling the links between diabetes, hypertension and kidney disease?
Anna Solini, Pisa, Italy

 

The overdriven glomerulus as a CV risk factor

 

Diabetic kidney disease in Asia: a growing threat

 

Clinical Practice Guideline on management of patients with diabetes and advanced chronic kidney disease
Maria Jose Soler Romeo, Barcelona, Spain

 

Acute kidney injury in the perioperative period

 

Prevention of AKI in oncology

 

Omics in AKI diagnosis

 

CEPD COURSES

 

Primary and Secondary Glomerulonephritis, vasculitis and auto-immune diseases
1. Minimal change disease and FSGS
2. Membranous Nephropathy
3. IgA Nephropathy
4. Vasculitides
5. Lupus Nephritis

 

CKD

 

Hypertension, Diabetes and CV Disease in CKD
1. Inflammation in CKD: cures at last?
2. Progress in the prevention and cure of diabetic nephropathy
3. Prognosis by risk calculators in CKD and in ESRD
4. Certainties and uncertainties about BP targets in CKD and ESRD patients
5. LV dysfunction with preserved Ejection Fraction in CKD: epidemiology, mechanism(s) and therapy

 

Bone Mineral disorders in CKD
1. How to prevent fractures in CKD? This could include the relevant parts of the updated KDIGO guidelines that changed considerably on this point
2. Are we inducing dynamic bone disease, and is that a problem?
3. Is FGF23 outdated?
4. Don’t forget our old friend Vitamin D, which could include the position of novel formulation of non-active vitamin D

 

Genetic Diseases and Rare Diseases
1. Genomic studies in monogenic and kidney stone disease
2. Genomic studies in adult CKD patients
3. Recent GWAS of kidney function markers
4. Polycystic kidney disease: new genes and clinical studies
5. Update on tubular and tubulointerstitial diseases

 

Basic and Transitional Nephrology
1. Kidney diseases at single cell level
2. The new age of kidney imaging
3. New models of kidney development and regeneration
4. How we survive acute injury and develop chronic disease: kidney, heart and liver not so different after all
5. Optogenetic control of inflammation in acute kidney injury

 

Nephropathology
1. Renal Biopsy: pitfalls
2. FSGS on renal biopsy: why an integrated approach to diagnosis is necessary
3. Atypical post-streptococcal GN and complement
4. Diabetic Nephropathy versus Kidney Diseases in Diabetics
5. The histopathologic spectrum of obesity-related glomerulopathy
6. Update on fibrillary and immunotactoid glomerulopathy
7. Renal side effects of novel anti-cancer drugs
8. Tubulointerstitial infiltrates in glomerular diseases
9. How to diagnose chronic TCMR in kidney transplants: Banff and the evidence

 

Haemodialysis and Vascular Access
Vascular access
1. Prevention and treatment of central venous catheter infections
2. New developments in vascular access, what can we expect for the future? Maturation, thrombosis prevention etc.
3. Recent guidelines on vascular access: ERBP, KDIGO, Eur Soc Vasc Surg,
Haemodialysis
1. Dialysis care: personalized or universal? (Focus on PROMs, so discuss SONG, ICHOM, etc. and how to implement this in daily care?)
2. HDF in children: what can we learn from paediatric studies
3. How to increase home and self-care haemodialysis?

 

Renal Transplantation
1. Can this person receive a kidney: what is the minimal workup that should be done in a healthy kidney transplant candidate?
2. How long this patient with previous cancer should wait before being wait-listed?
3. How can I evaluate this extended criteria kidney according to ECD, DCD, KDRI?
4. How should I prevent CMV disease and BK PVN in 2019?
5. How should I personalise maintenance therapy according to donor/recipient factors?

 

AKI
1. Volume management throughout the course of AKI: Risk – Oliguria – RRT – Polyuria
2. AKI in geriatric population and in frailty
3. AKI in austere environments
4. Biopsy in AKI: WHEN and WHY?: Indicated / non-indicated / contraindicated?
5. Recent clinical trials and update in AKI

 

Peritoneal Dialysis
1. PD catheter insertion and complications
2. How to prescribe APD
3. Prevention, diagnostics and treatment of peritonitis
4. Update on PD solutions
5. Changes in peritoneal structure and function with time on PD

 

Electrolytes and urolithiasis
1. Disorders of sodium and water
2. Hypo- and Hyperkalemia
3. Disorders of calcium and magnesium
4. Acid-Base disturbances and stones (case-based)
5. Stones and electrolytes (case-based)

 

ERA-EDTA Registry
1. Different flavours in RCTs and their analyses
2. Pros and cons of surrogate outcomes in RCTs
3. Mendelian randomization to enable causal inference in observational studies
4. Directed acyclic graphs (DAGs) to address confounding
5. The health economic toolbox in nephrology

 

 

European Renal Association - European Dialysis and Transplant Association (ERA-EDTA)
Data Privacy Statement

During the congress, attendees, exhibitors and others may be photographed and videotaped by ERA-EDTA or its partners capturing the event. Some of these photographs or videos may be displayed by the ERA-EDTA or its partners in future publications or materials connected with the event. If you do not wish for your image to be displayed by the ERA-EDTA, please contact the ERA-EDTA in writing at secretariat@era-edta.org . Without contradictory instructions from your side, you hereby grant the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA), the irrevocable right to use your image, voice, name, photographs, and video for purposes related to Scientific and Educational Purposes. You hereby release, waive and discharge the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) its employees and independent contractors from any and all demands, claims, causes of action, damages and liabilities directly or indirectly arising out of any use of your image, voice or name pursuant to the foregoing rights grant.